From 'Catching Up and Breaking Through' to 'Leading the Layout': How Shenzhen is Becoming a Global Innovation Hub for Pharmaceutical and Medical Device Industries

Currently serves as Executive Director and General Manager of Guangzhou Shangjun Investment Consulting Co., Ltd., while also holding the positions of Standing Committee Member of the Medical Innovation and Translation Expert Committee of the Guangdong Medical Association, and Executive Secretary-General of the China-Europe Science and Technology Investment Promotion Association.

Focusing on investment and ecosystem development in the healthcare industry, we have established an international financial innovation platform for life sciences. This one-stop platform integrates consulting, investment, in-depth project services, and resource integration to facilitate the commercialization of innovative scientific and technological achievements originating from universities, research institutes, and medical institutions. By linking and fostering close collaboration with innovative enterprises, investment firms, medical institutions, service providers, think tanks, and government organizations, we are committed to building a globally leading life sciences ecosystem.

Master’s degree from Nanyang Technological University, Singapore; Fellow of the Association of Chartered Certified Accountants (FCCA).

With over a decade of experience in project investment, M&A, and management, I have held financial management positions at the headquarters of several multinational corporations, including Fortune 500 companies, and served as Director of Strategic Investment at a publicly listed company, where I was responsible for strategy formulation and investment and M&A activities. During my tenure at the Shenzhen Angel FOF, I focused on investing in the biopharmaceutical industry and building its ecosystem, leading and participating in investments in biopharmaceutical projects such as Imunofend Bio, Guanxin Bio, Yuanshendi Bio, Hongxin Bio, and Boyin Bio. Furthermore, I actively empowered the incubation and growth of early-stage seed and angel projects, providing post-investment management and services to more than 300 biopharmaceutical and medical device companies invested by subsidiary funds.

B.S. in Chemistry from Nanjing University, Ph.D. in Chemistry from Cornell University, and Postdoctoral Fellow in the joint program between Tsinghua University and Shenzhen Capital Group (SCGC). Previously served as a Researcher at the Center for Integrated Nanotechnologies, Los Alamos National Laboratory, and as an Investment Manager at the SCGC China-US Fund. Has invested in dozens of venture capital projects both domestically and internationally (covering the United States, the United Kingdom, Israel, China, and other regions), with a focus on medical devices, digital health, life science tools, and innovative drugs. Possesses extensive experience in medical technology translation and project incubation investment. Representative portfolio companies include GRAIL, Oxford Nanopore, Northcore Life Sciences, Genetron Health, and Juxin Medical.

With over 10 years of investment experience in the healthcare industry. Previously served as Managing Director at Jinhe Capital, where he led investments in numerous projects, including Haobio, Dymind, Wowent, Zhonghan Shengtai, General Biosystems, Normandy Biotech, ClearMed Biotech, Molab Biotech, Dyingjia Technology, Zhongchi Weiye, and Jingliang Technology.